Shots:
- Ionis has completed enrollment in Cohort 1 (n=136; 2 to <18yrs.) of the global P-III (REVEAL) study assessing obudanersen (ION582) in pts with AS with genetic confirmation of either a UBE3A deletion or UBE3A mutation
- The Cohort 2 comprises adult pts (18 to ≤50yrs.) living with AS, with enrollment expected to be completed in Q3’26, while topline data from the REVEAL study is expected in H2’27
- Ionis also plans to advance obudanersen into the P-III (CHAMPION) study in AS pts with uniparental disomy or imprinting defect genotypes, with initiation expected before the end of 2026
Ref: Businesswire | Image: Ionis | Press Release
Related News: Ionis’ Tryngolza Receives the US FDA Approval for Patients with Severe Hypertriglyceridemia
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
